Clinical management of tuberous sclerosis complex over the lifetime of a patient

Michael Frost¹
John Hulbert²

¹Minnesota Epilepsy Group, PA, St Paul, MN, USA; ²Urologic Physicians, PA, Edina, MN, USA

Abstract: Tuberous sclerosis complex (TSC) is a genetic disorder characterized by nonmalignant tumors (hamartomas) that can occur in various organ systems, including the brain, kidneys, lungs, skin, eyes, and heart. Clinical manifestations of TSC can occur at any age, thereby making the diagnosis difficult. No typical disease presentation is known, and the clinical presentation usually differs between pediatric and adult patients. Furthermore, variable penetrance of the genetic mutation causes a range of disease severity from very mild to severe, and affected individuals can go undetected for years because many of the clinical manifestations of TSC lack specificity. Once a diagnosis is made, TSC management strategies should be tailored to address the symptoms and risks most relevant to the age of the patient. Improved understanding of the genetic basis of TSC and of the central issue of mTOR overactivation has led to use of pharmacotherapies such as the mTOR inhibitors everolimus and sirolimus in the treatment of TSC disease. In Phase II and III studies, everolimus has demonstrated efficacy and safety in the treatment of both brain (subependymal giant cell astrocytoma) and renal (angiomyolipoma) manifestations associated with TSC. It is important to bear in mind that TSC is a lifelong condition, and for those diagnosed as children, a continuum of care will be needed as they transition from pediatric to adult health services. Clearly identifying the likely differences among diagnosis, monitoring, and management of pediatric and adult patients with TSC is an important step in enabling efficiencies to be maximized without compromising the care provided to patients.

Keywords: mammalian target of rapamycin inhibitors, mTOR treatment, treatment strategies

Introduction

Tuberous sclerosis complex (TSC) is a genetic disorder with an incidence of approximately 1 in 5,000–6,000 live births and a prevalence between 1 million and 1.5 million people worldwide.¹,² It is characterized by nonmalignant tumors (hamartomas) that occur in various organ systems, including the brain, kidneys, lungs, skin, eyes, and heart. Clinical manifestations of TSC can occur at any age, thereby making the diagnosis difficult. No typical disease presentation is known, and the clinical presentation usually differs between pediatric and adult patients. Furthermore, variable penetrance of the genetic mutation causes a range of disease severity from very mild to severe, and affected individuals can go undetected for years because many of the clinical manifestations of TSC lack specificity. Once a diagnosis is made, TSC management strategies should be tailored to address the symptoms and risks most relevant to the age of the patient. Improved understanding of the genetic basis of TSC and of the central issue of mTOR overactivation has led to use of pharmacotherapies such as the mTOR inhibitors everolimus and sirolimus in the treatment of TSC disease. In Phase II and III studies, everolimus has demonstrated efficacy and safety in the treatment of both brain (subependymal giant cell astrocytoma) and renal (angiomyolipoma) manifestations associated with TSC. It is important to bear in mind that TSC is a lifelong condition, and for those diagnosed as children, a continuum of care will be needed as they transition from pediatric to adult health services. Clearly identifying the likely differences among diagnosis, monitoring, and management of pediatric and adult patients with TSC is an important step in enabling efficiencies to be maximized without compromising the care provided to patients.

Keywords: mammalian target of rapamycin inhibitors, mTOR treatment, treatment strategies
loss of the hamartin/tuberin dimer, which, in turn, results in constitutive activation of the mTOR complex 1 (mTORC1) and uncontrolled cellular growth and proliferation.\(^{10}\) There is evidence that mutations in the \(TSC2\) gene may result in more severe disease in multiple organs than mutations in the \(TSC1\) gene.\(^{3}\) Improved understanding of the genetic basis of TSC and of the central issue of mTOR overactivation has led to the development of new pharmacotherapies directly targeting the affected pathways and has considerably changed the options available for managing the disease.

Clinical manifestations of TSC can occur at any age, thereby making the diagnosis difficult. No typical disease presentation is known, and the clinical presentation usually differs between pediatric and adult patients. Furthermore, variable penetrance of the genetic mutation causes a range of disease severity from very mild to severe, and in affected individuals, the condition can go undetected for years because many of the clinical manifestations of TSC lack specificity. The diagnosis of a patient with TSC is dependent on the presence of a constellation of symptoms, or on a \(TSC1\) or \(TSC2\) pathogenic mutation.\(^{11,12}\) Once the diagnosis is made, TSC management strategies should be tailored to address the symptoms and risks most relevant to the age of the patient. It is important to bear in mind that TSC is a lifelong condition, and for those diagnosed as children, a continuum of care will be needed as they transition from pediatric to adult health services.\(^{13}\) Details regarding common clinical manifestations of TSC over a patient’s lifetime are discussed below. In addition, the role of mTOR inhibitors and other management strategies currently utilized to treat these manifestations are discussed with consideration of age-appropriate therapy.

**TSC manifestations over a patient’s lifetime**

TSC gene penetrance is approximately 100%; however, clinical manifestations of the disease may appear at different ages (Table 1) and severity can change over the lifetime of a patient.\(^{14–16}\) For example, angiomyolipoma lesion size and renal complications have been shown to increase with age.\(^{17}\) In addition, symptoms can vary between family members with TSC, and it is important to recognize the different manifestations likely to be seen among pediatric, adolescent, and adult patients.

Cardiac rhabdomyoma is one of the earliest manifestations of TSC, developing typically around week 22 to 28 of gestation.\(^{18}\) This tumor occurs in up to approximately 50%–70% of patients with TSC, primarily during the fetal and early neonatal periods.\(^{3,19–21}\) In a large database collected by the Tuberous Sclerosis Alliance on 1,187 patients, 461 patients had cardiac rhabdomyoma, of which 42 cases were diagnosed by fetal ultrasound.\(^{22}\) In a retrospective chart review by Staley et al, patients diagnosed during the first week of life presented with \(\geq 1\) cardiac rhabdomyoma.\(^{23}\) Most babies diagnosed with a cardiac rhabdomyoma will go on to be diagnosed with TSC.\(^{19,20}\) These lesions are usually asymptomatic and tend to regress spontaneously with increasing age;\(^{19,21}\) however, in a small percentage of patients, they cause symptoms such as outflow obstruction, valvular dysfunction, or arrhythmia.\(^{19–21,23,24}\) Among 16 patients with prenatal cardiac rhabdomyoma (identified between weeks 17 and 33), two patients were identified as the result of fetal arrhythmia.\(^{23}\) Patients may be treated for cardiac rhabdomyoma; everolimus may be effective in causing regression.\(^{24}\)

Abnormalities of the central nervous system associated with TSC typically manifest in childhood and can lead to problematic neurological and psychological issues, including epilepsy, cognitive deficits, and autism.\(^{2}\) Central nervous system anatomical abnormalities include subependymal giant cell astrocytomas (SEGAs), subependymal nodules (SENs), cortical tubers, and changes to the microarchitecture of the brain.\(^{1,12,25}\) Cortical tubers are a hallmark of TSC;\(^{2}\) they often develop before birth and occur in more than 80% of patients.\(^{1}\)

### Table 1 Age of TSC manifestation appearance\(^{14,14}\)

<table>
<thead>
<tr>
<th>Approximate age of appearance (years)</th>
<th>Prenatal</th>
<th>Birth</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>10</th>
<th>20</th>
<th>30</th>
<th>40</th>
<th>50</th>
<th>...</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuber</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEG A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac rhabdomyoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facial angiofibroma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shagreen patch</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ungual fibroma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal angiomyolipoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary LaM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retinal hamartoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** LAM, lymphangioleiomyomatosis; SEG A, subependymal giant cell astrocytoma; SEN, subependymal nodule; TSC, tuberous sclerosis complex.
Identified SENs and SEGAs develop from childhood through adolescence and have a similar histology, although SEGAs are differentiated by their larger size and serial growth. SEGAs occur in 5%–20% of patients with TSC; their usual location in the region of the foramen of Monro can eventually block the flow of cerebrospinal fluid, leading to acute or subacute hydrocephalus with associated morbidity and mortality.\(^2\)

Cortical tubers and associated microanatomical abnormalities in the central nervous system have been linked to the occurrence of seizures,\(^26\)–\(^28\) which are experienced by a large percentage of patients with TSC.\(^4,29\) TSC-associated epilepsy is likely to appear during the first year of life; it is often severe, progressive, and resistant to treatment and is more likely to impact cognitive abilities than non-TSC–related epilepsy.\(^29\)–\(^31\)

Skin abnormalities are a common early manifestation of TSC.\(^4\) In childhood, the most common skin complications are hypomelanotic macules (occurring in more than 90% of patients with TSC).\(^32,33\) Shagreen patches and facial angiofibromas also usually develop during childhood. Angiofibromas typically appear from 3–4 years of age and progressively worsen as a patient gets older; shagreen patches are usually apparent before 10 years of age and increase in number as a patient ages.\(^33\)–\(^35\) Ungual fibromas (Koenen tumors) may develop from adolescence into early adulthood.\(^4,33,34\) Skin lesions can negatively impact a patient’s quality of life, confidence, and psychological well-being. On occasion, the lesions may bleed and become infected.\(^33\)

Retinal hamartomas are another manifestation seen early in childhood.\(^36\) They are usually asymptomatic and are not progressive, but they may obstruct vision in some patients.\(^4\)

Renal manifestations of TSC are common, occurring in more than 80% of patients with TSC.\(^37\)–\(^39\) Renal angiomyolipoma is the most common lesion encountered, but cystic renal disease also occurs frequently;\(^37,39,40\) renal cancer has a similar rate of occurrence as the general population, but on average it occurs 25 years sooner in those with TSC, than the general population.\(^31\)–\(^43\)

Angiomyolipoma occurs in up to 80% of patients with TSC, typically starting in the first decade of life, with a median age at diagnosis of 10–11 years.\(^3,37\)–\(^40,44\) Renal disease seems more severe with TSC2 mutation and in association with constitutional deletions involving TSC2 and PKD1.\(^3,45\) Contiguous gene syndrome may result in renal insufficiency (although only 1%–2% of patients with TSC have severe renal insufficiency).\(^34,45\) Overall, however, the morbidity and mortality reported with renal lesions associated with TSC are of great significance; renal manifestations are a common cause of death in children and the most common cause of death in adults with TSC.\(^46\)

Lymphangioleiomyomatosis (LAM) is a pulmonary disorder that typically presents in early adulthood, with a mean age of symptom onset of 30–35 years.\(^2,47\)–\(^50\) It occurs almost exclusively in women,\(^47,49\)–\(^51\) although rare cases have been reported in men.\(^52,53\) It is characterized by diffuse infiltration of the lungs by smooth muscle cells and gradual replacement of the pulmonary parenchyma with cysts. Patients usually present with progressive dyspnea on exertion or recurrent pneumothorax.\(^2,48\)–\(^51,54\) The incidence (based on radiologic surveys) in women with TSC is in the range of 26%–48%.\(^44,55\) To clearly differentiate between TSC-associated LAM and spontaneous LAM (sLAM), TSC diagnostic criteria were recently amended and now require the presence of additional TSC features when both LAM and angiomyolipoma are present.\(^12\) Diagnosis of LAM may be aided by detection of vascular endothelial growth factor (VEGF)–D, an angiogenic biomarker that is elevated in patients with LAM.\(^36,57\)

Several other organs may also be involved in TSC, although more rarely or with less associated morbidity. Hamartoma can occur in bones, jaw, and liver, and dental pitting has been reported more frequently in older patients with TSC than in the general population.\(^38\)–\(^40\) Nonrenal hamartomas and the presence of >3 dental enamel pits are considered minor features of TSC that should be sought during diagnostic workup.\(^12\) Angiomyolipoma may occur outside of the kidneys but less commonly than in the kidneys.\(^51,62\) Because of their relative specificity to TSC, the presence of ≥2 angiomyolipomatosis, regardless of whether they are renal, is considered a major feature of TSC.\(^12\)

**Recent progress with targeted mTOR treatment**

Improved understanding of the genetic basis of TSC and of the central issue of mTOR overactivation has led to development of new pharmacotherapies that enable new management strategies for TSC. The mTOR inhibitors everolimus and sirolimus (rapamycin) have been investigated for the treatment of SEGAs and angiomyolipoma in patients with TSC, as well as for other manifestations, including seizures, LAM, and skin lesions. Everolimus has demonstrated efficacy in treating both SEGAs and angiomyolipoma associated with TSC in Phase II and III studies.\(^63\)–\(^65\) Everolimus (Afinitor\(^8\)) has been approved by the US Food and Drug Administration (FDA) for use in pediatric and adult patients with TSC who have SEGAs that requires therapeutic intervention but cannot be curatively resected, and in adults with renal angiomyolipoma and TSC not requiring immediate surgery.\(^56\)
Although it is not FDA approved for these treatments, sirolimus has demonstrated efficacy in a few case reports and a small (n=25) open-label study in patients with TSC-associated angiomylipoma, LAM, and SEGA.67-69

**Current management strategies in TSC – continuum of care**

It is important to recognize the differences between pediatric and adult patients with TSC with respect to diagnosis, monitoring, and appropriate management. TSC is a multifaceted disorder that can manifest in different ways throughout the life of the individual, and a multidisciplinary approach to the clinical management of TSC is required.13

Unless symptoms requiring attention are noted, such as arrhythmia or obstruction, minimal monitoring or management is recommended in neonates identified with rhabdomyoma.13 Pediatricians and general practitioners need to be aware that cardiac lesions generally do not worsen into adulthood, and follow-up should continue until the lesions decrease in size.13 Therefore, repeated testing and specialist referrals may not be needed over time, although cardiologists are useful for diagnosis and for consultation if symptomatic lesions are noted.

Neurological manifestations should be managed from birth to adulthood.11 Prevention of early-onset seizures, if possible, may improve a patient’s quality of life over the long term by reducing the morbidity often associated with epilepsy. In patients with TSC who have infantile spasms, vigabatrin has become the first-line therapy of choice, whereas in the non-TSC setting, adrenocorticotropic hormone (ACTH) is the first-line therapy of choice.70,71 Additionally, there is some evidence to suggest mTOR inhibitors may ameliorate or prevent seizures in TSC as demonstrated in two Phase I/II clinical studies evaluating everolimus in patients with SEGAs, and a case series evaluating both sirolimus and everolimus in patients with SEGAs;63,72-74 however, more robust studies are needed in this area. Other options for poorly controlled or refractory epilepsy include consumption of a ketogenic diet, surgical excision of tubers, vagus nerve stimulation, and corpus callosotomy.75 Treating epilepsy early may reduce the negative impact of early-onset seizures on later neurological functioning.70

Teaching parents to recognize seizures is a key element in achieving early diagnosis.13,70 Identification of electroencephalographic (EEG) seizures through the use of EEG monitoring in young infants may allow very early detection of abnormalities and initiation of preventive therapy.13,70 Additional significant neurological manifestations of TSC include neurobehavioral and cognitive difficulties such as mental retardation, autism, and learning difficulty, for which patients should be comprehensively assessed at diagnosis.13 Individuals with TSC are often of normal or near normal intellect and may exhibit obsessive-compulsive tendencies, generalized and social anxiety, shifting attention, and problems with multistep reasoning, or they may have profound mental retardation.2 A retrospective analysis examining psychiatric and behavioral disorders in patients with TSC identified 62 of 157 evaluable patients with confirmed psychiatric comorbidity.76 Psychiatric conditions included behavioral disorders (intermittent explosive disorder, oppositional defiant disorder, and self-injurious behavioral disorder), autism spectrum disorders, anxiety disorders, attention-deficit/hyperactivity disorder, and mood and thought disorders.79 On average, each patient was diagnosed with two psychiatric conditions (mean 2.42±1.27 diagnoses/patient).76 Management of psychiatric conditions includes the use of antipsychotics, antidepressants, and anticonvulsants with mood-stabilizing properties and is often associated with overall improvement or stabilization of psychiatric symptoms.76

Monitoring for the development or progression of potentially life-threatening conditions in the central nervous system such as SEGAs is also warranted.13 Patients should undergo regular brain imaging at least until adulthood.13 Symptomatic or enlarging SEGAs should be surgically excised when possible.13,77 For growing but otherwise asymptomatic SEGAs, or for SEGAs requiring intervention that is not amenable to resection, everolimus therapy can be considered to reduce SEGAs volume.13,66

To monitor eye health in patients with identified ophthalmologic lesions, annual ophthalmologic evaluation is recommended.13 As with cardiac lesions, health providers should be aware that retinal lesions usually do not get worse as the patient grows up, so repeated evaluations every 6 months are not needed. Similarly, more frequent assessment in children receiving vigabatrin for seizures (to monitor for potential ophthalmologic toxicity, as recommended by the FDA) is now considered of limited benefit in the absence of specific clinical concerns.13

Renal angiomylipoma requires close monitoring and careful management in both childhood and adult life.13 Although it is often asymptomatic, the nature of angiomylipoma with fragile aneurysmal blood vessels surrounded by soft adipose tissue can lead to spontaneous and severe renal hemorrhage78 and can be life threatening—a situation that is more frequent as the size increases to >4 cm.79 Furthermore, some angiomylipomata have low fat content and are difficult to differentiate radiologically from malignant renal tumors.
It is regrettable that in the past, far too frequently in both instances, this has resulted in nephrectomy, which in a condition that is bilateral and almost always benign should be the last resort. Fortunately, nowadays, both therapeutic embolization and, for those for whom embolization is not possible, nephron-sparing, minimally invasive surgical techniques (partial nephrectomy or ablative therapy), allied with greater understanding of TSC by physicians, patients, families, guardians, and caregivers, have enabled avoidance of nephrectomy, except as a last resort.15

Atypical (ie, low fat content) angiomyolipoma has presented a particular diagnostic challenge because of the radiological difficulty associated with differentiating it from renal cell cancer.80 However, greater understanding of TSC by radiologists, attention to the growth rate of the lesion, understanding that the incidence of atypical angiomyolipoma/renal cell cancer in TSC is 50:1, and safer biopsy techniques with HMB45 staining (specific for angiomyolipoma) should greatly aid diagnosis.80,81 A few angiomyolipomata appear to metastasize despite benign pathology; this may be a feature of multicentric origin or of actual metastasis.82,83 Treatment with everolimus can now be considered for asymptomatic, growing angiomyolipomata greater than 3 cm in diameter, as long as emergency intervention is not required;11 everolimus has demonstrated significantly greater angiomyolipoma response rates compared with placebo in Phase III clinical trials.84–86 Additionally, time to angiomyolipoma progression was statistically significantly longer in patients taking everolimus compared with those taking placebo.65

Identification and management of LAM are required almost exclusively for women in adulthood, usually from the third to fourth decade onward. mTOR inhibitors are recommended for the treatment of TSC-associated LAM in patients with moderate-to-severe lung disease or rapid progression; for patients with respiratory failure, lung transplantation is considered.13 The efficacy and safety of mTOR inhibitors such as everolimus and sirolimus have been examined in clinical trials, but the numbers of patients included have been low.55,84 Ongoing and future studies will enhance our understanding of the clinical benefits of mTOR inhibitors in the treatment of LAM. In the Phase III trial of everolimus in patients with angiomyolipoma associated with TSC or sLAM, 28% of patients in the everolimus arm and 18% in the placebo arm had LAM.65 By week 24, lung function had deteriorated less in patients receiving everolimus than in those given placebo, but differences were small (diffusion capacity for carbon monoxide [DLCO] −3% vs −8%; forced expiratory volume in 1 second [FEV1] −1% vs −4%) and interpretation was difficult in light of the small patient numbers and the short duration of the study.65 One open-label trial of sirolimus in patients with angiomyolipoma associated with TSC or sLAM reported some improvement from baseline in respiratory measures,69 although another reported no effect on pulmonary function.85

Future direction

Limited resources are available for research because of lack of funding or other priorities; therefore, it will become increasingly important to target treatment of TSC to ensure that it is as effective as possible. Early diagnosis and proactive treatment strategies initiated before the development of symptoms are becoming increasingly important.12 Use of everolimus as neoadjuvant therapy to reduce tumor volume as a means of improving surgical outcomes should be considered. Antiepileptic drug treatment administered before the development of clinical seizures was effective in reducing the onset of seizures and seizure severity and was associated with improved mental outcomes.86 Infants received vigabatrin (100–150 mg/kg/day) within 1 week after active epileptic discharges appeared on EEG (ie, preventative treatment), or the same dosage regimen was started within 1 week after the onset of clinical seizures (standard treatment).86 At 24 months of age, a significantly higher percentage of patients with epilepsy who received preventive treatment were seizure-free compared with patients with epilepsy who received standard treatment (P<0.0003). Mean IQ scores were significantly higher (P<0.05) and the percentage of patients with intellectual disability was significantly lower in the preventive treatment group (P=0.031).86 No patients in the preventive treatment group developed moderate, severe, or profound intellectual disability at 24 months of age.86

Clearly identifying the likely differences between diagnosis, monitoring, and management of pediatric and adult patients with TSC is an important step in enabling efficiencies to be maximized without compromising care provided to patients. The aim should be to enable an effective continuum of care for patients with TSC and their families as they transition from childhood into adulthood. Specialized TSC transition clinics that treat both children and adults regardless of organ system involvement could improve continuity of care for all patients with TSC, but particularly the more severely affected.13 Parents are the most effective advocates for young children with TSC, but as children mature into adolescence and adulthood, the need for comprehensive specialized care in one place is increased. All TSC facilities need to have the capability of addressing both medical requirements and psychosocial issues affecting individuals and their families.13
Avoiding unnecessary testing (although, at present, only 1–2% of patients with TSC develop end stage renal disease) can further reduce costs without compromising care.13

Acknowledgments
Editorial assistance was provided by ApotheCom (funded by Novartis Pharmaceuticals Corporation).

Disclosure
Michael Frost has no conflicts of interest to disclose. John Hulbert serves on the speakers’ bureau for Novartis Pharmaceuticals Corporation, for which he may receive remuneration, and is a member of the National Scientific Advisory Board of the Tuberous Sclerosis Alliance, for which he receives no compensation.

References